Morgan Stanley analyst Patrick Wood upgraded Insulet to Overweight from Equal Weight with a price target of $234, up from $185. With the stock down about 35% on a mixture of GLP-1 concerns and higher for longer treasury rates, Insulet has had a very challenging 2023, but the shares have been “overly punished” on GLP-1 worries and the company has “a number of exciting growth vectors as we move into 2024,” the analyst tells investors.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on PODD:
- Insulet price target lowered to $214 from $257 at Barclays
- Early notable gainers among liquid option names on November 6th
- Early notable gainers among liquid option names on November 3rd
- Insulet price target lowered to $240 from $330 at Wells Fargo
- Insulet price target lowered to $175 from $355 at Canaccord